Not Tagged
Not Tagged
['ovarian', 'brca']
check it out: eipd and trial-level meta-analysis of parp inhibitor maintenance after 1st line ct for ovarian cancer. absolute gain in 2y pfs: 31% for mbrca1/2, 17% for hrd, 9% for hrp. hrp: unmet therapeutic needs. presented at #asco23 
Medical Oncologist - Instituto do Câncer do Estado de São Paulo @ICESP_ - Oncologia D’Or #BreastCancer #GynecologicCancer